HQ: Cambridge, MA, USACEO: Andrew BellingerHeadcount: 200+vervetx.com ↗
Funding Summary
Total Funding
$600M+
Latest Valuation
~$800M (public market cap)
About
Using base editing to develop one-time treatments for cardiovascular disease by permanently turning off genes that cause high cholesterol (PCSK9, ANGPTL3). Lead program VERVE-101 in clinical trials.
Products
base-editing-cardiovascular
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →